,i  #aacth ,,congress  #ast ,session    
,h4 ,r4 #bcja  ,,in ,,the ,,house ,,of  
,,representatives  ,june #f1 #bjac ,mr4 
,reed 7for himself1 ,ms4 ,slaughter1 and
 ,mr4 ,collins of ,new ,york7 introduced
 the following bill2 which was referred 
to the ,committee on ,energy and        
,commerce  ,a ,,bill  ,to amend the     
,public ,health ,service ,act to enhance
 the clinical trial registry data bank  
reporting requirements and enforcement  
measures4  #a4 ,short title ,this ,act  
may be cited as the ,clinical ,trial    
,cancer ,mission #bjbj ,act4  #b4       
,enhancing clinical trial registry data 
bank reporting requirements and         
enforcement measures  7a7 ,clarification
 that clinical trial registry data bank 
requirements apply regardless of trial  
outcomes ,section #djb7;j77#a77;,a77i7  
of the ,public ,health ,service ,act    
7#db ,u4,s4,c4 #bhb7;j77#a77;,a77i77 is 
amended by inserting before the period  
at the end the following 1 whether or   
not such a clinical trial results in a  

positive or negative outcome4  7b7      
,application to grants from ,department 
of ,defense ,section                    
#djb7;j77#e77;,a77i7 of such ,act 7#db  
,u4,s4,c4 #bhb7;j77#e77;,a77i77 is      
amended by inserting the ,department of 
,defense or after agency of4  7c7       
,enhanced enforcement ,section          
#djb7;j77#e77;,a7 of such ,act 7#db     
,u4,s4,c4 #bhb7;j77#e77;,a77 is amended 
by adding at the end the following new  
clause3  7v7 ,enhanced enforcement      
,after the #cj-;day period described in 
clause 7iii71 if the head of an agency  
referred to in clause 7i71 as           
applicable1 verifies that a grantee has 
not submitted clinical trial information
 as described in clause 7ii71 with      
respect to an applicable clinical trial 
that is funded in whole or in part by a 
grant from the agency1 such grantee--   
7,i7 shall not be eligible to receive   
any remaining funding for the grant or  
funding for a future ,federal grant     
until such time as the grantee comes    

into compliance with all applicable     
reporting requirements under this       
subsection2 and  7,,ii7 shall be liable 
to the ,united ,states for repayment of 
any amount provided under the grant for 
the clinical trial for which the grantee
 failed to comply with such reporting   
requirements4  4